Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Join SI Premium – FREE
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $14.42 million versus the consensus estimate of $11.96 million.
For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regency Centers (REG) Tops Q2 EPS by 2c
- Bogota Financial Corp. (BSBK) Reports Q2 EPS of $0.06
- enVVeno Medical (NVNO) Misses Q2 EPS by 537c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
